Impact of short-term 1,25-dihydroxyvitamin D3 on the chemopreventive efficacy of erlotinib against oral cancer

Cancer Prevention Research

Volumn 8, Issue 9, 2015, Pages 765-776

  Bothwell, Katelyn D ^a   Shaurova, Tatiana ^a   Merzianu, Mihai ^a   Suresh, Amritha ^a   Kuriakose, Moni A ^a   Johnson, Candace S ^a   Hershberger, Pamela A ^a   Seshadri, Mukund ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 NITROQUINOLINE 1 OXIDE; CALCITRIOL; ERLOTINIB; GADOLINIUM PENTETATE MEGLUMINE; PROTEIN KINASE B; 4-NITROQUINOLONE-1-OXIDE; ANTINEOPLASTIC AGENT; CARCINOGEN; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; QUINOLONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INCIDENCE; CANCER PREVENTION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DYSPLASIA; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MOUSE; MOUTH CANCER; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SHORT COURSE THERAPY; TUMOR VOLUME; ANIMAL; C57BL MOUSE; CANCER TRANSPLANTATION; CARCINOMA, SQUAMOUS CELL; DISEASE COURSE; DOWN REGULATION; DRUG ADMINISTRATION; HEAD AND NECK NEOPLASMS; METABOLISM; MOUTH NEOPLASMS; SCID MOUSE;

4-NITROQUINOLINE-1-OXIDE; ANIMALS; ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS; CALCITRIOL; CARCINOGENS; CARCINOMA, SQUAMOUS CELL; DISEASE PROGRESSION; DOWN-REGULATION; DRUG ADMINISTRATION SCHEDULE; ERLOTINIB HYDROCHLORIDE; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MAGNETIC RESONANCE IMAGING; MICE; MICE, INBRED C57BL; MICE, SCID; MOUTH NEOPLASMS; NEOPLASM TRANSPLANTATION; QUINOLONES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84941756497     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-14-0454     Document Type: Article

References (46)

1. Normanno N, Bianco C, Strizzi L, Mancino M, Maiello MR, De Luca A, et al. The ErbB receptors and their ligands in cancer: an overview. Curr Drug Targets 2005;6:243-57.
2. Molinolo AA, Amornphimoltham P, Squarize CH, Castilho RM, Patel V, Gutkind JS. Dysregulated molecular networks in head and neck carcinogenesis. Oral Oncol 2009;45:324-34.
3. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-78.
4. Vermorken JB, Trigo J, Hitt R, Koralewski P, Diaz-Rubio E, Rolland F, et al. Open-label, uncontrolled multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007;25:2171-7.
5. Gross ND, Bauman JE, Gooding WE, Deng W, Thomas SM, Wang L, et al. Erlotinib, erlotinib-sulindac versus placebo: a randomized, double-blind, placebo-controlled window trial in operable head and neck cancer. Clin Cancer Res 2014;20:3289-98.
6. Grandis JR, Tweardy DJ. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 1993;53:3579-84.
7. Taoudi Benchekroun TM, Saintigny P, Thomas SM, El-Naggar AK, Papadimitrakopoulou V, Ren H, et al. Epidermal growth factor receptor expression and gene copy number in the risk of oral cancer. Cancer Prev Res 2010;3:800-9.
8. Saba NF, Hurwitz SJ, Kono S, Yang CS, Zhao Y, Chen Z, et al. Chemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase Ib and pharmacokinetic study. Cancer Prev Res 2014;7:283-91.
9. Rosenthal EL, Chung TK, Carroll WR, Clemons L, Desmond R, Nabell L. Assessment of erlotinib as adjuvant chemoprevention in high-risk head and neck cancer patients. Ann Surg Oncol 2014;21:4263-9.
10. Zhang X, Zhang H, Tighiouart M, Lee JE, Shin HJ, Khuri FR, et al. Synergistic inhibition of head and neck tumor growth by green tea (2)-epigallocatechin-3-gallate and EGFR tyrosine kinase inhibitor. Int J Cancer 2008;123:1005-14.
11. Saba NF, Hammond A, Shin DM, Khuri FR. Moving toward bioadjuvant approaches to head and neck cancer prevention. Int J Radiat Oncol Biol Phys 2007;69:S132-5.
12. Bikle DD, Pillai S. Vitamin D, calcium, and epidermal differentiation. Endocrine Rev 1993;14:3-19.
13. Reichekl H, Koeffler HP, Norman AW. The role of the vitamin D endocrine system in health and disease. New Engl J Med 1989;320:980-91.
14. Weinstein SJ, Purdue MP, Smith-Warner SA, Mondul AM, Black A, Ahn J, et al. Serum 25-hydroxyvitamin D, vitamin D binding protein and risk of colorectal cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Int J Cancer 2015;136:E654-64.
15. Hershberger PA, Modzelewski RA, Shurin ZR, Rueger RM, Trump DL, Johnson CS. 1, 25-dihydroxycholecaliferol (1, 25-D3) inhibits the growth of squamous cell carcinoma and down-modulates p21 (Waf1/Cip1) in vitro and in vivo. Cancer Res 1999;59:2644-9.
16. Johnson CS, Muindi JR, Hershberger PA, Trump DL. The antitumor efficacy of calcitriol: preclinical studies. Anticancer Res 2006;26:2543-9.
17. Deeb KK, Trump DL, Johnson CS. Vitamin D signaling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer 2007;7:684-700.
18. Bernardi RJ, Johnson CS, Modzelewski RA, Trump DL. Antiproliferative effects of 1a, 25-dihydroxyvitamin D (3) and vitamin D analogs on tumorderived endothelial cells. Endocrinology 2002;143:2508-14.
19. Freudlsperger C, Burnett JR, Friedman JA, Kannabiran VR, Chen Z, Van Waes C. EGFR-PI3K-AKT-mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapy. Expert Opin Ther Targets 2011;15:63-74.
20. McGuire TF, Trump DL, Johnson CS. Vitamin D (3)-induced apoptosis of murine squamous cell carcinoma cells. Selective induction of caspasedependent MEK cleavage and up-regulation of MEKK-1. J Biol Chem 2001;276:26365-73.
21. Seshadri M, Merzianu M, Tang H, Rigual NR, Sullivan M, Loree TR, et al. Establishment and characterization of patient tumor-derived head and neck squamous cell carcinoma xenografts. Cancer Biol Ther 2009;8:2275-83.
22. Kanojia D, Vaidya MM. 4-nitroquinoline-1-oxide induced experimental oral carcinogenesis. Oral Oncol 2006;42:655-67.
23. Vitale-Cross L, Molinolo AA, Marin D, Younis RH, Maruyama T, Patel V, et al. Metformin prevents the development of oral squamous cell carcinomas from carcinogen-induced premalignant lesions. Cancer Prev Res 2012;5:562-73.
24. Menezes RJ, Cheney RT, Husain A, Tretiakova M, Loewen G, Johnson CS, et al. Vitamin D receptor expression in normal, premalignant, and malignant human lung tissue. Cancer Epidemiol Biomarkers Prev 2008;17:1104-10
25. Jayaprakash V, Sullivan M, Merzianu M, Rigual NR, Loree TR, Popat SR, et al. Autofluorescence-guided surveillance for oral cancer. Cancer Prev Res 2009;2:966-74.
26. De Graeff A, De Leeuw JR, Ros WJ, Hordijk GJ, Blijham GH, Winnubst JA. Long-term quality of life of patients with head and neck cancer. Laryngoscope 2000;110:98-106.
27. 3 and its analogs in breast, prostate and colorectal cancer. Endocr Relat Cancer 2013;20:R31-47.
28. 3 on oral squamous cell carcinomas in vitro. J Dietary Suppl 2014;11:145-54.
29. 3) to inhibit carcinogenesis in the hamster buccal pouch model. Arch Otolaryngol Head Neck Surg 2007;133:1149-52.
30. Stumpf WE, Sar M, Reid FA, Tanaka Y, De Luca HF. Target cells for 1, 25-dihydroxyvitamin in intestinal tract, stomach, kidney, skin, pituitary, and parathyroid. Science 1979;206:1188-90.
31. Yuan FN, Valiyaparambil J, Woods MC, Tran H, Pant R, Adams JS, et al. Vitamin D signaling regulates oral keratinocyte proliferation in vitro and in vivo. Int J Oncol 2014;44:1625-33.
32. Grimm M, Cetindis M, Biegner T, Lehman M, Munz A, Teriete P, et al. Serum vitamin D levels of patients with oral squamous cell carcinoma and expression of vitamin D receptor in oral precancerous lesions and OSCC. Med Oral Patol Oral Cir Bucal 2015;2:e188-95.
33. 3 increase epidermal growth factor receptor gene expression in BT-20 breast carcinoma cells. Biochem Biophys Res Commun 1991;176:1-6.
34. 3 in human breast cancer cells. Cancer Res 1988;48:2734-9.
35. 3 is mediated by mutual modulation of receptor expression. Eur J Cancer 1998;34:2119-25.
36. Segaert S, Degreef H, Bouillon R. VitaminDreceptor expression is linked to cell cycle control in normal human keratinocytes. Biochem Biophys Res Commun 2000;279:89-94.
37. Cordero JB, Cozzolino M, Lu Y, Vidal M, Slatopolsky E, Stahl PD, et al. 1, 25-dihydroxyvitamin D down-regulates cell membrane growth- and nuclear growth-promoting signals by the epidermal growth factor receptor. J Biol Chem 2002;277:38965-71.
38. 3 treatment to diminish suppressor cells in head and neck cancer patients. Hum Immunol 2001;62:1282-93.
39. 3 treatment to stimulate immune infiltration into head and neck squamous cell carcinoma. Hum Immunol 2010;71:659-65
40. Szabo E. Primer: first do no harm - when is it appropriate to plan a cancer prevention clinical trial? Nat Clin Pract Oncol 2008;5:348-56.
41. Smith DC, Johnson CS, Freeman CC, Muindi J, Wilson JW, Trump DL. A phase I trial of subcutaneous calcitriol (1, 25-dihydroxycholecalciferol) in patients with advanced malignancy. Clin Cancer Res 1999;5:1339-45.
42. Fakih MG, Trump DL, Muindi JR, Black JD, Bernardi RJ, Creaven PJ, et al. A phase I pharmacokinetic and pharmacodynamic study of intravenous calcitriol in combination with oral gefitinib in patients with advanced solid tumors. Clin Cancer Res 2007;13:1216-23.
43. 3 in normal mice after systemic exposure to effective and safe antitumor doses. Oncology 2004;66:62-6.
44. Cassell A, Freilino ML, Lee J, Barr S, Wang L, Panahandeh MC, et al. Targeting TORC1/2 enhances sensitivity to EGFR inhibitors in head and neck cancer preclinical models. Neoplasia 2012;14:1005-14.
45. Shin DM, Zhang H, Saba NF, Chen AY, Nannapaneni S, Amin AR, et al. Chemoprevention of head and neck cancer by simultaneous blocking of epidermal growth factor receptor and cyclooxygenase-2 signaling pathways: preclinical and clinical studies. Clin Cancer Res 2013;19:1244-56.
46. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J 2008;22:659-61.